-
1
-
-
0034959207
-
Antihypertensive efficacy of candesartan in comparison to losartan: The CLAIM study
-
Bakris G, Gradman A, Reif M, Wofford M, Munger M, Harris S, Vendetti J, Michelson EL, Wang R, and CLAIM Study Investigators (2001) Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens (Greenwich) 3:16-21. (Pubitemid 32605752)
-
(2001)
Journal of Clinical Hypertension
, vol.3
, Issue.1
, pp. 16-21
-
-
Bakris, G.1
Gradman, A.2
Reif, M.3
Wofford, M.4
Munger, M.5
Harris, S.6
Vendetti, J.7
Michelson, E.L.8
Wang, R.9
-
2
-
-
78651266925
-
Effects of the novel angiotensin receptor blocker azilsartan medoxomil in patients with primary hypertension
-
Bakris GL, Sica D, Weber MA, White WB, Perez A, Cao C, and Kupfer S (2010) Effects of the novel angiotensin receptor blocker azilsartan medoxomil in patients with primary hypertension. J Clin Hypertens 12 (Suppl 1):A106-A107.
-
(2010)
J Clin Hypertens
, vol.12
, Issue.SUPPL. 1
-
-
Bakris, G.L.1
Sica, D.2
Weber, M.A.3
White, W.B.4
Perez, A.5
Cao, C.6
Kupfer, S.7
-
3
-
-
0027361358
-
1 angiotensin II receptor antagonists
-
DOI 10.1021/jm00074a018
-
Bernhart CA, Perreaut PM, Ferrari BP, Muneaux YA, Assens JL, Clément J, Haudricourt F, Muneaux CF, Taillades JE, and Vignal MA (1993) A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists. J Med Chem 36:3371-3380. (Pubitemid 23335701)
-
(1993)
Journal of Medicinal Chemistry
, vol.36
, Issue.22
, pp. 3371-3380
-
-
Bernhart, C.A.1
Perreaut, P.M.2
Ferrari, B.P.3
Muneaux, Y.A.4
Assens, J.L.A.5
Clement, J.6
Haudricourt, F.7
Muneaux, C.F.8
Taillades, J.E.9
Vignal, M.A.10
Gougat, J.11
Guiraudou, P.R.12
Lacour, C.A.13
Roccon, A.14
Cazaubon, C.F.15
Breliere, J.C.16
Le, F.G.17
Nisato, D.18
-
4
-
-
67449168119
-
Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling
-
Bhuiyan MA, Ishiguro M, Hossain M, Nakamura T, Ozaki M, Miura S, and Nagatomo T (2009) Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling. Life Sci 85:136-140.
-
(2009)
Life Sci
, vol.85
, pp. 136-140
-
-
Bhuiyan, M.A.1
Ishiguro, M.2
Hossain, M.3
Nakamura, T.4
Ozaki, M.5
Miura, S.6
Nagatomo, T.7
-
5
-
-
0028231547
-
Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series
-
DOI 10.1016/S0960-894X(01)81117-3
-
Bühlmayer P, Furet P, Criscione L, de Gasparo M, Whitebread S, Schmidlin T, Lattmann R, and Wood J (1994) Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series. Bioorg Med Chem Lett 4:29-34. (Pubitemid 24128681)
-
(1994)
Bioorganic and Medicinal Chemistry Letters
, vol.4
, Issue.1
, pp. 29-34
-
-
Buhlmayer, P.1
Furet, P.2
Criscione, L.3
De, G.M.4
Whitebread, S.5
Schmidlin, T.6
Lattmann, R.7
Wood, J.8
-
6
-
-
0347423198
-
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
-
Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute, and National High Blood Pressure Education Program Coordinating Committee. National Heart, Lung, and Blood Institute, and National High Blood Pressure Education Program Coordinating Committee
-
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute, and National High Blood Pressure Education Program Coordinating Committee. National Heart, Lung, and Blood Institute, and National High Blood Pressure Education Program Coordinating Committee(2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206-1252.
-
(2003)
Hypertension
, vol.42
, pp. 1206-1252
-
-
Chobanian, A.V.1
Bakris, G.L.2
Black, H.R.3
Cushman, W.C.4
Green, L.A.5
Izzo Jr., J.L.6
Jones, D.W.7
Materson, B.J.8
Oparil, S.9
Wright Jr., J.T.10
Roccella, E.J.11
-
7
-
-
0033824138
-
International Union of Pharmacology. XXIII. The angiotensin II receptors
-
de Gasparo M, Catt KJ, Inagami T, Wright JW, and Unger T (2000) International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52:415-472.
-
(2000)
Pharmacol Rev
, vol.52
, pp. 415-472
-
-
De Gasparo, M.1
Catt, K.J.2
Inagami, T.3
Wright, J.W.4
Unger, T.5
-
8
-
-
0036271824
-
Candesartan cilexetil: An update of its use in essential hypertension
-
Easthope SE and Jarvis B (2002) Candesartan cilexetil: an update of its use in essential hypertension. Drugs 62:1253-1287. (Pubitemid 34591101)
-
(2002)
Drugs
, vol.62
, Issue.8
, pp. 1253-1287
-
-
Easthope, S.E.1
Jarvis, B.2
-
10
-
-
0034285627
-
Lys(199) mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists
-
Fierens FL, Vanderheyden PM, Gáborik Z, Minh TL, Backer JP, Hunyady L, Ijzerman A, and Vauquelin G (2000) Lys(199) mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists. J Renin Angiotensin Aldosterone Syst 1:283-288.
-
(2000)
J Renin Angiotensin Aldosterone Syst
, vol.1
, pp. 283-288
-
-
Fierens, F.L.1
Vanderheyden, P.M.2
Gáborik, Z.3
Minh, T.L.4
Backer, J.P.5
Hunyady, L.6
Ijzerman, A.7
Vauquelin, G.8
-
11
-
-
0030480485
-
Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres
-
DOI 10.1021/jm960547h
-
Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, and Naka T (1996) Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem 39:5228-5235. (Pubitemid 27010313)
-
(1996)
Journal of Medicinal Chemistry
, vol.39
, Issue.26
, pp. 5228-5235
-
-
Kohara, Y.1
Kubo, K.2
Imamiya, E.3
Wada, T.4
Inada, Y.5
Naka, T.6
-
12
-
-
70349980161
-
Next generation multifunctional angiotensin receptor blockers
-
Kurtz TW and Klein U (2009) Next generation multifunctional angiotensin receptor blockers. Hypertens Res 32:826-834.
-
(2009)
Hypertens Res
, vol.32
, pp. 826-834
-
-
Kurtz, T.W.1
Klein, U.2
-
13
-
-
0026510753
-
Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action
-
Liu YJ, Shankley NP, Welsh NJ, and Black JW (1992) Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action. Br J Pharmacol 106:233-241.
-
(1992)
Br J Pharmacol
, vol.106
, pp. 233-241
-
-
Liu, Y.J.1
Shankley, N.P.2
Welsh, N.J.3
Black, J.W.4
-
14
-
-
34250350040
-
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
-
DOI 10.1097/HJH.0b013e3281fc975a, PII 0000487220070600000001
-
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, et al. (2007) 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105-1187. (Pubitemid 46924065)
-
(2007)
Journal of Hypertension
, vol.25
, Issue.6
, pp. 1105-1187
-
-
Mancia, G.1
De, B.G.2
Dominiczak, A.3
Cifkova, R.4
Fagard, R.5
Germano, G.6
Grassi, G.7
Heagerty, A.M.8
Kjeldsen, S.E.9
Laurent, S.10
Narkiewicz, K.11
Ruilope, L.12
Rynkiewicz, A.13
Schmieder, R.E.14
Boudier, H.A.J.S.15
Zanchetti, A.16
-
15
-
-
33745842894
-
Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor
-
DOI 10.1074/jbc.M602144200
-
Miura S, Fujino M, Hanzawa H, Kiya Y, Imaizumi S, Matsuo Y, Tomita S, Uehara Y, Karnik SS, Yanagisawa H, et al. (2006) Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem 281:19288-19295. (Pubitemid 44035433)
-
(2006)
Journal of Biological Chemistry
, vol.281
, Issue.28
, pp. 19288-19295
-
-
Miura, S.-I.1
Fujino, M.2
Hanzawa, H.3
Kiya, Y.4
Imaizumi, S.5
Matsuo, Y.6
Tomita, S.7
Uehara, Y.8
Karnik, S.S.9
Yanagisawa, H.10
Koike, H.11
Komuro, I.12
Saku, K.13
-
16
-
-
0028792103
-
Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist
-
Mizuno M, Sada T, Ikeda M, Fukuda N, Miyamoto M, Yanagisawa H, and Koike H (1995) Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 285:181-188.
-
(1995)
Eur J Pharmacol
, vol.285
, pp. 181-188
-
-
Mizuno, M.1
Sada, T.2
Ikeda, M.3
Fukuda, N.4
Miyamoto, M.5
Yanagisawa, H.6
Koike, H.7
-
17
-
-
0025884056
-
Efficient selection for high-expression transfectants with a novel eukaryotic vector
-
Niwa H, Yamamura K, and Miyazaki J (1991) Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193-199.
-
(1991)
Gene
, vol.108
, pp. 193-199
-
-
Niwa, H.1
Yamamura, K.2
Miyazaki, J.3
-
18
-
-
0027281668
-
Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist
-
DOI 10.1016/0006-2952(93)90420-2
-
Noda M, Shibouta Y, Inada Y, Ojima M, Wada T, Sanada T, Kubo K, Kohara Y, Naka T, and Nishikawa K (1993) Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol 46:311-318. (Pubitemid 23218618)
-
(1993)
Biochemical Pharmacology
, vol.46
, Issue.2
, pp. 311-318
-
-
Noda, M.1
Shibouta, Y.2
Inada, Y.3
Ojima, M.4
Wada, T.5
Sanada, T.6
Kubo, K.7
Kohara, Y.8
Naka, T.9
Nishikawa, K.10
-
19
-
-
77952304034
-
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)
-
Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, et al. (2009) The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 32:3-107.
-
(2009)
Hypertens Res
, vol.32
, pp. 3-107
-
-
Ogihara, T.1
Kikuchi, K.2
Matsuoka, H.3
Fujita, T.4
Higaki, J.5
Horiuchi, M.6
Imai, Y.7
Imaizumi, T.8
Ito, S.9
Iwao, H.10
-
20
-
-
0031566881
-
1 receptor
-
DOI 10.1016/S0014-2999(96)00837-0, PII S0014299996008370
-
Ojima M, Inada Y, Shibouta Y, Wada T, Sanada T, Kubo K, and Nishikawa K (1997) Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol 319:137-146. (Pubitemid 27051327)
-
(1997)
European Journal of Pharmacology
, vol.319
, Issue.1
, pp. 137-146
-
-
Ojima, M.1
Inada, Y.2
Shibouta, Y.3
Wada, T.4
Sanada, T.5
Kubo, K.6
Nishikawa, K.7
-
21
-
-
0033950686
-
Newly emerging pharmacologic differences in angiotensin II receptor blockers
-
Oparil S (2000) Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 13:18S-24S.
-
(2000)
Am J Hypertens
, vol.13
-
-
Oparil, S.1
-
22
-
-
0034760610
-
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension
-
Oparil S, Williams D, Chrysant SG, Marbury TC, and Neutel J (2001) Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 3:283-291, 318.
-
(2001)
J Clin Hypertens
, vol.3
-
-
Oparil, S.1
Williams, D.2
Chrysant, S.G.3
Marbury, T.C.4
Neutel, J.5
-
23
-
-
0029078461
-
Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism
-
Panek RL, Lu GH, Overhiser RW, Major TC, Hodges JC, and Taylor DG (1995) Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism. J Pharmacol Exp Ther 273:753-761.
-
(1995)
J Pharmacol Exp Ther
, vol.273
, pp. 753-761
-
-
Panek, R.L.1
Lu, G.H.2
Overhiser, R.W.3
Major, T.C.4
Hodges, J.C.5
Taylor, D.G.6
-
24
-
-
0034691035
-
Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay
-
DOI 10.1073/pnas.110142297
-
Parnot C, Bardin S, Miserey-Lenkei S, Guedin D, Corvol P, and Clauser E (2000) Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay. Proc Natl Acad Sci USA 97:7615-7620. (Pubitemid 30431512)
-
(2000)
Proceedings of the National Academy of Sciences of the United States of America
, vol.97
, Issue.13
, pp. 7615-7620
-
-
Parnot, C.1
Bardin, S.2
Miserey-Lenkei, S.3
Guedin, D.4
Corvol, P.5
Clauser, E.6
-
25
-
-
70349987109
-
Multivalent ligand-receptor interactions elicit inverse agonist activity of AT1 receptor blockers against stretch-induced AT1 receptor activation
-
Qin Y, Yasuda N, Akazawa H, Ito K, Kudo Y, Liao CH, Yamamoto R, Miura S, Saku K, and Komuro I (2009) Multivalent ligand-receptor interactions elicit inverse agonist activity of AT1 receptor blockers against stretch-induced AT1 receptor activation. Hypertens Res 32:875-883.
-
(2009)
Hypertens Res
, vol.32
, pp. 875-883
-
-
Qin, Y.1
Yasuda, N.2
Akazawa, H.3
Ito, K.4
Kudo, Y.5
Liao, C.H.6
Yamamoto, R.7
Miura, S.8
Saku, K.9
Komuro, I.10
-
26
-
-
48549095799
-
Angiotensin receptor blockers: Current status and future prospects
-
Ram CV (2008) Angiotensin receptor blockers: current status and future prospects. Am J Med 121:656-663.
-
(2008)
Am J Med
, vol.121
, pp. 656-663
-
-
Ram, C.V.1
-
27
-
-
0027744344
-
6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: Synthesis, biological activity, and structure-activity relationships
-
Ries UJ, Mihm G, Narr B, Hasselbach KM, Wittneben H, Entzeroth M, van Meel JC, Wienen W, and Hauel NH (1993) 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships. J Med Chem 36:4040-4051.
-
(1993)
J Med Chem
, vol.36
, pp. 4040-4051
-
-
Ries, U.J.1
Mihm, G.2
Narr, B.3
Hasselbach, K.M.4
Wittneben, H.5
Entzeroth, M.6
Van Meel, J.C.7
Wienen, W.8
Hauel, N.H.9
-
28
-
-
44949171907
-
Olmesartan medoxomil: A review of its use in the management of hypertension
-
DOI 10.2165/00003495-200868090-00005
-
Scott LJ and McCormack PL (2008) Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 68:1239-1272. (Pubitemid 351822113)
-
(2008)
Drugs
, vol.68
, Issue.9
, pp. 1239-1272
-
-
Scott, L.J.1
McCormack, P.L.2
-
29
-
-
0027431141
-
Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylate (TCV-116)
-
Shibouta Y, Inada Y, Ojima M, Wada T, Noda M, Sanada T, Kubo K, Kohara Y, Naka T, and Nishikawa K (1993) Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H- tetrazol-5-yl)biphenyl-4-yl] methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl] methyl]-1H-benzimidazole- 7-carboxylate (TCV-116). J Pharmacol Exp Ther 266:114-120.
-
(1993)
J Pharmacol Exp Ther
, vol.266
, pp. 114-120
-
-
Shibouta, Y.1
Inada, Y.2
Ojima, M.3
Wada, T.4
Noda, M.5
Sanada, T.6
Kubo, K.7
Kohara, Y.8
Naka, T.9
Nishikawa, K.10
-
30
-
-
79951995665
-
New angiotensin II receptor blocker azilsartan medoxomil: Comparison to valsartan
-
Sica D, White WB, Weber MA, Bakris GL, Perez A, Cao C, and Kupfer S (2010) New angiotensin II receptor blocker azilsartan medoxomil: comparison to valsartan. J Hypertens 28:e276.
-
(2010)
J Hypertens
, vol.28
-
-
Sica, D.1
White, W.B.2
Weber, M.A.3
Bakris, G.L.4
Perez, A.5
Cao, C.6
Kupfer, S.7
-
31
-
-
44949104716
-
Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension
-
Smith DH (2008) Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 68:1207-1225.
-
(2008)
Drugs
, vol.68
, pp. 1207-1225
-
-
Smith, D.H.1
-
32
-
-
70449484613
-
The evolving story of the RAAS in hypertension, diabetes and CV disease: Moving from macrovascular to microvascular targets
-
Steckelings UM, Rompe F, Kaschina E, and Unger T (2009) The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundam Clin Pharmacol 23:693-703.
-
(2009)
Fundam Clin Pharmacol
, vol.23
, pp. 693-703
-
-
Steckelings, U.M.1
Rompe, F.2
Kaschina, E.3
Unger, T.4
-
33
-
-
62949153839
-
Sartan-AT1 receptor interactions: In vitro evidence for insurmountable antagonism and inverse agonism
-
Van Liefde I and Vauquelin G (2009) Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol 302:237-243.
-
(2009)
Mol Cell Endocrinol
, vol.302
, pp. 237-243
-
-
Van Liefde, I.1
Vauquelin, G.2
-
34
-
-
73649209211
-
Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters
-
van Rossum JM (1963) Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn 143:299-330.
-
(1963)
Arch Int Pharmacodyn
, vol.143
, pp. 299-330
-
-
Van Rossum, J.M.1
-
35
-
-
0035254652
-
A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists
-
DOI 10.1016/S0006-2952(00)00546-3, PII S0006295200005463
-
Vauquelin G, Morsing P, Fierens FL, De Backer JP, and Vanderheyden PM (2001) A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists. Biochem Pharmacol 61:277-284. (Pubitemid 32126665)
-
(2001)
Biochemical Pharmacology
, vol.61
, Issue.3
, pp. 277-284
-
-
Vauquelin, G.1
Morsing, P.2
Fierens, F.L.P.3
De, B.J.-P.4
Vanderheyden, P.M.L.5
-
36
-
-
0034932549
-
A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM study II
-
DOI 10.1038/sj.jhh.1001205
-
Vidt DG, White WB, Ridley E, Rahman M, Harris S, Vendetti J, Michelson EL, Wang R, and CLAIM Study Investigators (2001) A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens 15:475-480. (Pubitemid 32640263)
-
(2001)
Journal of Human Hypertension
, vol.15
, Issue.7
, pp. 475-480
-
-
Vidt, D.G.1
White, W.B.2
Ridley, E.3
Rahman, M.4
Harris, S.5
Vendetti, J.6
Michelson, E.L.7
Wang, R.8
-
37
-
-
0027070825
-
Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies
-
Wienen W, Mauz AB, Van Meel JC, and Entzeroth M (1992) Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies. Mol Pharmacol 41:1081-1088. (Pubitemid 23026108)
-
(1992)
Molecular Pharmacology
, vol.41
, Issue.6
, pp. 1081-1088
-
-
Wienen, W.1
Mauz, A.B.M.2
Van, M.J.C.A.3
Entzeroth, M.4
-
38
-
-
0030049822
-
Nonpeptide angiotensin II receptor antagonists: Synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds
-
Yanagisawa H, Amemiya Y, Kanazaki T, Shimoji Y, Fujimoto K, Kitahara Y, Sada T, Mizuno M, Ikeda M, Miyamoto S, et al. (1996) Nonpeptide angiotensin II receptor antagonists: synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds. J Med Chem 39:323-338.
-
(1996)
J Med Chem
, vol.39
, pp. 323-338
-
-
Yanagisawa, H.1
Amemiya, Y.2
Kanazaki, T.3
Shimoji, Y.4
Fujimoto, K.5
Kitahara, Y.6
Sada, T.7
Mizuno, M.8
Ikeda, M.9
Miyamoto, S.10
-
39
-
-
38949137039
-
Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation
-
DOI 10.1038/sj.embor.7401157, PII 7401157
-
Yasuda N, Miura S, Akazawa H, Tanaka T, Qin Y, Kiya Y, Imaizumi S, Fujino M, Ito K, Zou Y, et al. (2008) Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep 9:179-186. (Pubitemid 351223456)
-
(2008)
EMBO Reports
, vol.9
, Issue.2
, pp. 179-186
-
-
Yasuda, N.1
Miura, S.-I.2
Akazawa, H.3
Tanaka, T.4
Qin, Y.5
Kiya, Y.6
Imaizumi, S.7
Fujino, M.8
Ito, K.9
Zou, Y.10
Fukuhara, S.11
Kunimoto, S.12
Fukuzaki, K.13
Sato, T.14
Ge, J.15
Mochizuki, N.16
Nakaya, H.17
Saku, K.18
Komuro, I.19
-
40
-
-
2942751868
-
Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II
-
DOI 10.1038/ncb1137
-
Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, Makita N, Iwanaga K, Zhu W, Kudoh S, et al. (2004) Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 6:499-506. (Pubitemid 38786592)
-
(2004)
Nature Cell Biology
, vol.6
, Issue.6
, pp. 499-506
-
-
Zou, Y.1
Akazawa, H.2
Qin, Y.3
Sano, M.4
Takano, H.5
Minamino, T.6
Makita, N.7
Iwanaga, K.8
Zhu, W.9
Kudoh, S.10
Toko, H.11
Tamura, K.12
Kihara, M.13
Nagai, T.14
Fukamizu, A.15
Umemura, S.16
Iiri, T.17
Fujita, T.18
Komuro, I.19
|